PCA
DGX icon

Providence Capital Advisors’s Quest Diagnostics DGX Stock Holding History

Providence Capital Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,509
Closed -$5.79M – 360
2024
Q1 		$5.79M Buy
43,509
+6,500
+18% +$843K 1.26% 32
2023
Q4 		$5.1M Buy
37,009
+1,400
+4% +$184K 1.22% 37
2023
Q3 		$4.34M Buy
35,609
+1,100
+3% +$147K 1.14% 43
2023
Q2 		$4.85M Buy
34,509
+3,894
+13% +$537K 1.23% 36
2023
Q1 		$4.33M Buy
30,615
+1,715
+6% +$245K 1.14% 47
2022
Q4 		$4.52M Buy
+28,900
New +$4.15M 1.22% 32
2020
Q2 		– Sell
-100
Closed -$8K – 205
2020
Q1 		$8K Buy
+100
New +$10.4K ﹤0.01% 182

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Providence Capital Advisors's DGX Position: Q2 2024 in Review

Providence Capital Advisors sold out of Quest Diagnostics (DGX) in Q2 2024, closing a stake of 43,509 shares — an estimated $5.79M sold.

Providence Capital Advisors first reported a position in DGX in Q1 2020 and held it in 7 quarters. The position peaked at $5.79M in Q1 2024. 838 funds tracked by Wall St. Rank hold DGX as of Q2 2024.

  • Providence Capital Advisors reported no remaining Quest Diagnostics position as of Q2 2024 after selling out during the quarter.
  • Providence Capital Advisors sold 43,509 Quest Diagnostics shares in Q2 2024, an estimated $5.79M.
  • Providence Capital Advisors first reported a position in Quest Diagnostics in Q1 2020 and held it in 7 quarters.
  • Providence Capital Advisors's Quest Diagnostics position peaked at $5.79M in Q1 2024.
  • 838 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2024.

Based on Providence Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.